Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
Shaji Kumar(Mayo Clinic), B G M Durie(Samueli Institute), Saad Z. Usmani(Memorial Sloan Kettering Cancer Center), Chaim Shustik(Spanish Head & Neck Cancer Cooperative Group), Laura Rosiñol(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Dominik Dytfeld, Efstathios Kastritis(National and Kapodistrian University of Athens), Juan José Lahuerta(Research Institute Hospital 12 de Octubre), J H Lee(Gachon University Gil Medical Center), Ravi Vij(Washington University in St. Louis), Sundar Jagannath(Mount Sinai Hospital), Heinz Ludwig(Wilhelminen Hospital), María‐Victoria Mateos(Hospital Clínico San Carlos), Ingemar Turesson(Spanish Head & Neck Cancer Cooperative Group), Daniel D. Waller(Terry Fox Research Institute), Parameswaran Hari(Medical College of Wisconsin), Niels W.C.J. van de Donk(Oncode Institute), Javier de la Rubia(Universitat de València), Meletios Α. Dimopoulos(Korea University), Evangelos Terpos(National and Kapodistrian University of Athens), Ulf‐Henrik Mellqvist, Xavier Leleu(Inserm), Hareth Nahi(Karolinska University Hospital), Albert Oriol(Institut Català d'Oncologia), Elizabeth O’Donnell(Harvard University), Hartmut Goldschmidt(Heidelberg University), Tomer M. Mark(University of Colorado Hospital), Charalampia Kyriakou(The Royal Free Hospital), Ashraf Badros(University of Maryland, Baltimore), Wee Joo Chng(National University of Singapore), Jens Hillengaß(Roswell Park Comprehensive Cancer Center), Michèle Cavo(Unknown), Markus Hansson(Lund University), Hyeon‐Seok Eom(National Cancer Center), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Meral Beksaç(Liv Hospital), Melissa Alsina(Moffitt Cancer Center), Jin Seok Kim(University of Ulsan), Shuji Ozaki(Tokushima Prefectural Central Hospital), Chang‐Ki Min(Sheba Medical Center), Philippe Moreau(Centre National de la Recherche Scientifique), K Kim(Samsung Medical Center), H M Lokhorst(University Medical Center Utrecht), Michel Delforge(KU Leuven), Enrique M. Ocio(Universidad de Salamanca)
Cited by 356
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k